What Is Considered a Low Dose of Testosterone?

What counts as a “low dose” of testosterone depends almost entirely on who is taking it and why. A dose considered modest for a man on testosterone replacement therapy could be many times higher than the dose prescribed to a postmenopausal woman, and the doses used in gender-affirming care for non-binary individuals sit in yet another range. The numbers differ by an order of magnitude or more across these contexts, which makes the question surprisingly hard to answer with a single figure.

Male Testosterone Replacement Therapy

For men diagnosed with low testosterone (hypogonadism), the goal of replacement therapy is to bring blood levels back into the normal range, generally somewhere between 300 and 1,050 ng/dL. No single testosterone formulation perfectly replicates the body’s natural daily rhythm of hormone release, but all approved therapies aim for that physiological window.¹ In this context, “low dose” usually refers to the lower end of what achieves that target.

With transdermal gels, a common starting point might be around 40 to 50 mg applied daily to the skin. One phase III trial used a starting gel dose of 46 mg on the upper arm and shoulder, and about 86% of participants landed within the 300–1,050 ng/dL target range after 90 days.² That starting dose is often considered a low-to-moderate entry point, with clinicians adjusting upward if blood levels remain below the target.

For injectable testosterone, the landscape is a bit different. Subcutaneous injections, typically given weekly or biweekly, can keep blood levels remarkably stable. In one study of men on subcutaneous testosterone, the average total testosterone level between injections was about 627 ng/dL, comfortably within the normal range.³ There is no universally agreed-upon cutoff that separates “low dose” from “standard dose” in men, but clinicians tend to think of low-dose TRT as the smallest amount needed to resolve symptoms while keeping blood levels in the lower half of the normal range. For intramuscular cypionate or enanthate, that might be in the neighborhood of 50 to 80 mg per week, while higher replacement doses can reach 100 to 200 mg weekly.

Why Delivery Method Matters

You cannot compare milligram numbers across different formulations without understanding how each one gets testosterone into the bloodstream. A 50 mg daily gel dose does not deliver 50 mg of testosterone into your body. Most of the hormone sits on the skin and never absorbs; bioavailability for transdermal products is often only around 10%. Injections, by contrast, deliver nearly all of the dose into systemic circulation, though the release profile varies with the ester (cypionate, enanthate, undecanoate) and the injection site.

This is why a 46 mg gel dose and a 75 mg weekly injection can both be considered “low” even though the raw numbers look different. What matters clinically is the serum testosterone level the dose produces, not the number on the label. When your doctor checks your blood levels a few weeks into therapy, the result tells them whether the dose is low, adequate, or too high, regardless of the formulation.

Testosterone Therapy in Women

The numbers drop dramatically when the patient is a woman. In women, normal circulating testosterone is roughly a tenth to a twentieth of what is considered normal in men, so therapeutic doses are proportionally tiny. The most-studied low dose for women is 300 micrograms per day of transdermal testosterone, which is 0.3 mg, delivered through a patch or cream. That is less than one percent of a typical male TRT gel dose.

Research on this dose has focused heavily on hypoactive sexual desire disorder (HSDD) in postmenopausal women. A systematic review of high-quality trials found that 300 µg/day of transdermal testosterone was effective for managing HSDD in both surgically and naturally menopausal women, with minimal side effects.⁴ Randomized, placebo-controlled trials have confirmed this dose works in women whose androgen levels are low due to surgical menopause.⁵

Higher doses given to women in research settings, like 25 mg per week by injection, produced measurable increases in lean body mass (averaging about 1.8 kg over placebo) without significant changes in total fat.⁶ But even that weekly injection is far below what a man would receive. In women, the clinical definition of “low dose” essentially means the smallest amount that restores testosterone to the upper end of the normal female range without pushing it into male territory.

Low-Dose Testosterone in Gender-Affirming Care

Gender-affirming testosterone therapy has traditionally been dosed to produce full masculinization as quickly as is safely achievable. But a growing number of people, especially those with non-binary gender identities, want something more gradual or partial. They may want voice deepening or mild fat redistribution without full facial hair growth, or they may simply prefer slower changes they can evaluate as they go. This has created a distinct clinical category sometimes called “low-dose T.”

In a retrospective study of non-binary individuals on transdermal testosterone for at least six months, the median starting dose was 25 mg of gel daily, with some starting as low as 12.5 mg. The median dose at the most recent follow-up had risen slightly to 37.5 mg, and the median blood testosterone level in this group was about 11 nmol/L (roughly 317 ng/dL), which sits in the lower half of the male reference range.⁷ The vast majority, 87%, stayed on these lower doses over the long term rather than escalating to the full doses recommended in existing guidelines.⁸

For context, standard masculinizing testosterone therapy for transgender men typically aims for serum testosterone of 10 to 35 nmol/L, and may use gel doses of 50 mg or more daily, or injections of 50 to 100 mg weekly. The low-dose approach in non-binary care deliberately targets the lower end of that range, or even just above it, and accepts a slower pace of physical changes. Research on body composition in trans men found that both low-dose and higher-dose groups experienced a decrease in body fat percentage and an increase in lean body mass during the first year, though the higher-dose group gained lean mass faster initially.⁹ Over the long term, the differences narrowed, suggesting that low-dose testosterone can achieve meaningful physical changes given enough time.

Safety at Low Versus High Doses

Testosterone’s side effects are dose-dependent, which is one of the strongest practical arguments for using the lowest effective dose in any context. Two areas get the most clinical attention: blood thickening and cholesterol changes.

Hemoglobin and hematocrit, the measures of how packed your blood is with red cells, rise in a linear fashion as the testosterone dose goes up. This response is even more pronounced in older men.¹⁰ When hematocrit climbs too high, blood becomes thicker and the risk of clotting events rises. Keeping the dose low enough to stay within the normal testosterone range is one of the main strategies for avoiding this problem. Clinicians typically monitor blood counts every few months during the first year of therapy.

The effect on cholesterol is more nuanced. A meta-analysis of intramuscular testosterone in men with low testosterone found modest decreases in total cholesterol and LDL cholesterol, but also a small drop in protective HDL cholesterol of about 4 mg/dL.¹¹ A broader review noted that the most dramatic HDL drops have been seen with supraphysiologic doses in young men and among athletes using anabolic steroids, not with standard replacement therapy. Transdermal testosterone at doses that simply normalize blood levels in older men did not appear to affect HDL at all.¹²

In women, even low doses can nudge lipid markers. One study of low-dose testosterone in women found that HDL cholesterol and apolipoprotein A1 decreased compared to controls, while VLDL cholesterol increased. Total cholesterol, LDL, and triglycerides did not change, and clotting factors were unaffected.¹³ The clinical significance of these small shifts in women on long-term low-dose therapy is still debated, but they underscore why monitoring matters even at the doses considered safe.

What Low-Dose Testosterone Does Not Seem to Do

One area where low-dose testosterone has repeatedly disappointed is cognition. There is a persistent idea that testosterone therapy sharpens thinking, improves spatial reasoning, or lifts mood in people with declining levels. The evidence does not support this at low or moderate doses. A trial of oral testosterone undecanoate in older men with low-normal testosterone found that although bioavailable testosterone increased and muscle mass went up after 12 months, there was no improvement in any cognitive measure, mood, or quality of life compared to placebo.¹⁴ Similarly, a dose-response trial in hysterectomized women found no significant changes in spatial ability, verbal fluency, verbal memory, or executive function at any dose tested, even after adjusting for baseline differences.¹⁵ If your goal is cognitive enhancement, low-dose testosterone is unlikely to deliver it.

Fertility and the Signals Testosterone Sends

One of the most misunderstood aspects of testosterone therapy is its effect on fertility in men. Even at low doses, exogenous testosterone tells the brain that circulating hormone levels are adequate, which suppresses the signals that drive sperm production. This can reduce sperm counts dramatically, sometimes to zero. The effect is usually reversible after stopping therapy, but recovery can take months or longer.

For men who want to maintain fertility while on testosterone, co-administration of human chorionic gonadotropin (hCG) has been studied as a workaround. In one study, adding low-dose hCG to testosterone replacement therapy maintained levels of testosterone within the testes, the local environment sperm production depends on, and no patient became azoospermic (completely lacking sperm) during the combination therapy.¹⁶ This strategy does not guarantee normal fertility, but it offers a significant safety net compared to testosterone alone.

The takeaway for anyone considering even a modest testosterone dose is that “low” does not mean “safe for fertility.” Any amount of exogenous testosterone can suppress sperm production. If having children is a possibility you want to preserve, this is a conversation to have before starting therapy, not after noticing problems.

Microdosing in Anti-Doping

In competitive sports, “low dose” takes on an entirely different meaning. Athletes looking to gain an edge sometimes use tiny amounts of testosterone, called microdoses, specifically chosen to boost performance while staying below the detection thresholds of drug testing. These doses are much smaller than what a clinic would prescribe for hypogonadism and are designed to clear the body quickly.

Detecting these microdoses is an ongoing arms race. A study testing a single transdermal testosterone application in healthy volunteers found that advanced isotope ratio mass spectrometry (IRMS) could pick up the exogenous testosterone even when the standard urinary testosterone-to-epitestosterone ratio did not budge. Serum testosterone levels measured alongside urine samples improved detection further.¹⁷ The challenge is particularly acute because testosterone is chemically identical to what the body makes naturally, making micro-dose misuse one of the hardest doping scenarios to catch.¹⁸

In women, the detection window for testosterone microdosing is similarly narrow. Research involving healthy female volunteers found that after a short course of testosterone, urine and serum markers returned to near-baseline within two to four days, though certain blood markers related to red blood cell production stayed elevated for up to two weeks.¹⁹ Combining multiple types of tests, including serum testosterone, urine ratios, and blood cell measurements, improved accuracy to about 93% correct classification, but no single test was foolproof on its own. Newer sampling methods like dried blood spots are being explored to make testing simpler and potentially more sensitive.²⁰

How Dose-Response Works in Practice

Testosterone does not work like a light switch where a threshold dose turns on all effects at once. Different tissues respond at different points along the dosing curve. Animal research has shown that androgen-responsive organs increase in size in a dose-dependent fashion, but the response eventually saturates at high concentrations, meaning there are diminishing returns as the dose climbs.²¹ In practical terms, this means that doubling a dose does not double the clinical effect. It does, however, tend to double the exposure to side effects.

This non-linear relationship is part of why clinicians emphasize the minimum effective dose. At the low end, you can often get most of the symptom relief, whether that is improved energy, sexual function, or body composition, while minimizing the hematocrit creep and lipid shifts that become more pronounced at higher doses. The sweet spot varies from person to person, which is why testosterone therapy always involves follow-up blood work and dose adjustments rather than a one-size-fits-all prescription.

For athletes using supraphysiologic amounts, the doses are not even in the same conversation. Reports describe some users taking anywhere from 50 to 2,000 mg per week, sustained for years at a time.²² At those levels, the dose-response curve for side effects steepens considerably, and the risk of serious cardiovascular, hepatic, and dermatological harm increases in ways that legitimate low-dose therapy rarely approaches.